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RESEARCH ARTICLE
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine
concentrating capacity. Increased circulating vasopressin (AVP) concentrations are sup-
posed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients
have a more severely impaired urine concentrating capacity in comparison to other patients
with chronic kidney disease at a similar level of kidney function, with consequently an
enhanced AVP response to water deprivation with higher circulating AVP concentrations.
Methods
15 ADPKD (eGFR<60) patients and 15 age-, sex- and eGFR-matched controls with IgA
nephropathy (IgAN), underwent a water deprivation test to determine maximal urine concen-
trating capacity. Plasma and urine osmolality, urine aquaporin-2 (AQP2) and plasma AVP
and copeptin (a surrogate marker for AVP) were measured at baseline and after water depri-
vation (average 16 hours). In ADPKD patients, height adjusted total kidney volume (hTKV)
was measured by MRI.
Results
Maximal achieved urine concentration was lower in ADPKD compared to IgAN controls (533
±138 vs. 642±148 mOsm/kg, p = 0.046), with particularly a lower maximal achieved urine
urea concentration (223±74 vs. 299±72 mmol/L, p = 0.008). After water deprivation, plasma
osmolality was similar in both groups although change in plasma osmolality was more pro-
found in ADPKD due to a lower baseline plasma osmolality in comparison to IgAN controls.
Copeptin and AVP increased significantly in a similar way in both groups. AVP, copeptin
and urine AQP2 were inversely associated with maximal urine concentrating in both groups.
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Conclusions
ADPKD patients have a more severely impaired maximal urine concentrating capacity with
a lower maximal achieved urine urea concentration in comparison to IgAN controls with sim-
ilar endogenous copeptin and AVP responses.
Introduction
One of the first clinical features in autosomal dominant polycystic kidney disease (ADPKD) is
an impaired urine concentrating capacity that occurs prior to kidney function decline [1–3].
The mechanism leading to decreased urine concentrating capacity is not fully understood.
Probably abnormalities in the renal medullary architecture, due to cyst formation and expan-
sion, play an important role. In a previous study, we found that already in the early stages of
disease there is an impaired maximal urine concentrating capacity, which is accompanied by
increased plasma osmolality and vasopressin (AVP) levels during water deprivation, in com-
parison to healthy controls [4].
AVP is secreted from the pituitary gland when plasma osmolality increases. AVP subse-
quently binds to the vasopressin V2 receptor of the collecting ducts which stimulates water
reabsorption by migration of aquaporin-2 (AQP2) to the apical cell membrane. Besides being
important for water homeostasis, AVP has deleterious effects in ADPKD. AVP has been
shown to increase intracellular cAMP, which promotes cell proliferation and cyst formation
[5]. Indeed, animal models and a large randomized controlled trial in ADPKD patients showed
that blocking the vasopressin V2 receptor reduces the rate of cyst growth and renal function
loss [6–9].
In the present study, we hypothesized that in advanced stages of ADPKD, the increase in
AVP in response to water deprivation is stronger than might be expected from impaired kid-
ney function per se [10,11]. To study urine concentrating capacity and AVP response in
ADPKD, we performed water deprivation tests in ADPKD patients with impaired kidney
function and in a control group of patients with IgA nephropathy (IgAN), matched for age,
sex and eGFR. In addition to AVP, copeptin was measured as a surrogate marker for AVP,
since copeptin is more stable than AVP [12–14].
Subjects and Methods
Study population
Eligible for this study were patients with ADPKD, as diagnosed using the revised Ravine crite-
ria [15], aged between 18–65 years and with an estimated GFR (eGFR) <60 ml/min/1.73m2.
The control group consisted of IgA nephropathy (IgAN) patients, matched for eGFR, age and
sex. The diagnosis of IgAN was based on renal biopsy or clinical history and laboratory values
in accordance with clinical practice. IgAN patients were eligible when they were in a stable
phase of their disease, as defined by proteinuria <1 g/d and eGFR loss5 ml/min/1.73m2 in
the previous year and without use of immunosuppressive medication. Exclusion criteria for
both patient groups were: use of medications or concomitant diseases that influence urine con-
centration capacity other than ADPKD or IgAN (e.g., diuretics, lithium and diabetes mellitus),
factors that may influence urine concentration capacity (e.g. smoking, menstruation, urinary
tract infection, pregnancy, and consumption of4 units of alcohol per day) or active cardio-
vascular disease (e.g. angina pectoris), which is a contraindication for DDAVP administration.
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This study was approved by our institutional review board, the Medical Ethical Committee of
the University Medical Center Groningen, and was performed in adherence to the Declaration
of Helsinki. All participants gave written informed consent.
Study protocol
All patients routinely collected a 24-hour urine sample the day preceding the water deprivation
test. Patients underwent a standard prolonged water deprivation test, based on the protocol
originally described by Miller et al. [16]. The day before the water deprivation test and during
the test, participants were not allowed to smoke, drink alcohol or consume caffeine-containing
products. At the day of the test, a baseline spot urine sample was collected at 5 p.m. and blood
was drawn for direct biochemical evaluation. Plasma was separated and stored at -80˚C for
later assessment of copeptin and AVP. Thereafter, participants received a standardized meal
and were not allowed to eat or drink anymore until the end of the water deprivation test.
Patients spent the evening and the night at home. The following day patients returned to the
hospital at 8 a.m., after 14 hours of thirsting. Patients spent the day in the hospital, with spot
urine samples being collected every hour until two consecutive measurements showed an
increase in urine osmolality30 mOsm/kg. After reaching this plateau, participants received
an intramuscular injection of 2 mcg DDAVP, a synthetic replacement for AVP. Two hours
after injection, blood and urine samples were collected. Urine osmolality that was measured at
this time point was used to define maximal urine concentrating capacity. Two hours after
injection of DDAVP, participants were allowed to drink and eat ad libitum. To ensure patient
safety during the water deprivation test stopping criteria were defined as reaching a body
weight reduction >3% or a plasma sodium >150 mmol/L.
Measurements
Standard biochemical evaluation was performed in fresh urine and plasma samples, using a
Roche Modular Autoanalyser (Hitachi, Tokyo, Japan). Plasma and urine osmolality were mea-
sured directly via determination of freezing point depression using an Osmometer (Arkray,
Kyoto, Japan), with an intra-assay coefficient of variation <1.0%. eGFR was calculated with
the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation [17].
Blood for AVP and copeptin measurement was drawn into a chilled EDTA tube, and
immediately centrifuged at 4˚C and stored at −80˚C until assay. AVP was measured by RIA
after an extraction using ODS-silica (DiaSorin, Stillwater, MN). The lower limit of detection
was 0.2 pg/ml and the intra-assay coefficient of variation 3.5%. Copeptin was measured using a
sandwich immunoassay (B.R.A.H.M.S. AG, Hennigsdorf/Berlin, Germany), with a lower limit
of detection of 0.4 pmol/L and intra-assay coefficient of variation of 4 and 3% for the copeptin
concentrations of 15 and 50 pmol/L, respectively. Urine aquaporin-2 (AQP2) concentration
was measured by a direct ELISA [18] using rabbit-anti-AQP2 antibody (Santa Cruz Biotech-
nology, Dallas, TX, USA) with a lower limit of detection of 6.67 ng/mL and intra-assay coeffi-
cient of variation of 6.1%. In all ADPKD patients MR imaging was performed, using a
standardised abdominal MR imaging protocol without the use of intravenous contrast [19].
Total kidney volume (TKV) was assessed using Analyze Direct 8.0 software (AnalyzeDirect,
Inc., Overland Park, KS, USA). Total kidney volume was divided by height to calculate the
height adjusted total kidney volume (hTKV).
Statistical analyses
Normally distributed variables are expressed as mean±SD, non-normally distributed vari-
ables as median (IQR). Differences in baseline characteristics between ADPKD and IgAN
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patients were calculated with a Chi-square test for categorical data, and for continuous data
with a Student’s t-test or a Mann-Whitney U test in case of non-normally distributed data.
Percentage change between baseline and maximal urine concentration were tested in the
overall population and within study groups using a one sample t-test with 0% change as ref-
erence value. Linear regression analyses were performed to test associations between plasma
and urine osmolality, AVP, copeptin, AQP2-creatinine ratio, hTKV, albumin-creatinine
ratio (ACR) and urine-to-plasma urea ratio (U/P Urea). AVP, copeptin, AQP2-creatinine
ratio, hTKV, ACR and U/P Urea were log (ln) transformed to fulfill the requirement of nor-
mal distribution of the residuals for regression analysis. To investigate differences between
the two study groups the categorical variable ‘study group’ (ADPKD vs. IgAN) was added to
the regression analysis. Furthermore, to investigate whether associations between copeptin
and other study variables were different between the study groups, interaction was tested by
adding product terms including ‘study group’ and the independent variable to this model.
Univariate (crude) linear regression models are presented with the correlation coefficient
whereas for multiple variable models the standardized regression coefficient beta (St. β) is
given.
All statistical analyses were performed using SPSS 22 (SPSS Statistics, Inc., Chicago, IL, U.S.
A.). A p-value of<0.05 was considered to indicate statistical significance and all statistical tests
were 2-tailed.
Results
Before water deprivation at baseline
Baseline characteristics with respect to age, sex and eGFR were similar between ADPKD
patients and the IgAN controls, indicating that matching was successful (Table 1). Blood
pressure was slightly higher and 24-hour urine volume was particularly higher in ADPKD
patients than in IgAN controls. Total solute, urea and creatinine excretion did not differ
between the groups, indicating that both groups had similar nutritional intake and muscle
mass. Baseline plasma osmolality, copeptin and AVP were similar in both study groups,
although plasma osmolality tended to be lower in ADPKD patients than in IgAN controls
(Table 2). A spot urine sample collected before start of the water deprivation test, showed
less concentrated urine with lower urine osmolality, sodium and urea in ADPKD patients
than IgAN controls (Table 3).
After water deprivation at maximal urine concentration
All patients underwent a standard prolonged water deprivation test. None of the patients
met the safety stopping criteria during the test. Plasma osmolality increased significantly in
ADPKD patients but not in IgAN controls. Upon water deprivation, copeptin and AVP
increased significantly in ADPKD patients and IgAN controls in a similar way (Table 2).
Urine osmolality increased both in ADPKD patients and IgAN controls (Table 3). However,
the maximal achieved urine osmolality was significantly lower in ADPKD patients in com-
parison to IgAN controls, especially due to a decreased urine urea concentration. AQP2 at
maximal urine concentration was similar in both groups and decreased in a similar way dur-
ing water deprivation. After DDAVP administration, urine osmolality increased in ADPKD
patients with an average of +4.7% (p = 0.001). However, numerically this increase was small
and similar to the increase in the IgAN control group (+4.5%, p = 0.01, ADPKD vs. IgAN:
p = 0.4).
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Associations between copeptin, AVP, plasma and urine osmolality and
AQP2
At baseline and at maximal urine concentration, copeptin and AVP concentrations were
strongly associated (R = 0.72 and R = 0.78, respectively, both p<0.001). Furthermore, copeptin
was associated with plasma osmolality, a stimulus for AVP release, both at baseline and at max-
imal urine concentration Table 4 and Fig 1). No interactions by study group for the associa-
tions between copeptin and plasma osmolality were found (Table 4). The aforementioned
associations were also tested for AVP instead of copeptin, which rendered essentially similar
results, albeit that the associations were less strong (Table 4).
Urine osmolality was inversely associated with copeptin at maximal urine concentration
(Fig 1). Addition of the categorical variable study group to the linear regression model, with
maximal urine osmolality as dependent variable, showed that ADPKD patients had a 105
mOsmol/kg lower maximal urine osmolality compared with the control group at a similar
copeptin level (St. β = -0.35, p = 0.01, Table 5). No interactions by study group for the associa-
tion between copeptin and urine osmolality was found. AVP was associated with maximal
urine osmolality in a similar way, with a 119 mOsmol/kg lower maximal urine osmolality in
ADPKD patients at a similar AVP level (St. β = -0.40, p = 0.02, Table 5).
Table 1. Characteristics of the overall population, and of ADPKD and IgA Nephropathy patients separately.
Overall n = 30 ADPKD n = 15 IgAN n = 15 P-value
Age (y) 49±8 49±7 49±9 0.91
Male (%) 66.7 66.7 66.7 1.00
BMI (kg/m2) 28±4 27±3 29±4 0.10
BSA (m2) 2.06±0.20 2.00±0.19 2.13±0.18 0.06
Systolic blood pressure (mmHg) 129±13 134±14 123±8 0.02
Diastolic blood pressure (mmHg) 81±9 85±10 78±6 0.03
Using antihypertensives (%) 93.3 93.3 93.3 1.00
eGFR (mL/min/1.73m2) 47±14 46±11 48±17 0.38
TKV (L) 1.7 (0.9–2.5)
hTKV (L/m) 1.0 (0.5–1.3)
24-hour urine
Volume (L) 2.3±0.9 2.8±0.9 1.9±0.5 0.002
Osmolality (mOsmol/kg) 422±144 347±133 496±117 0.003
Osmolality excretion (mOsmol/24h) 431±99 441±88 421±111 0.59
Urea (mmol/L) 190±69 146±53 233±55 <0.001
Urea excretion (mmol/24h) 194±54 201±64 187±43 0.50
Creatinine (mmol/L) 6.7±2.8 5.1±1.9 8.4±2.6 0.001
Creatinine excretion (mmol/24h) 6.7±1.3 6.5±1.2 6.9±1.5 0.39
Albumin excretion (mg/24h) 95 (25–360) 47 (16–288) 148 (68–522) 0.045
Albumin/creatinine ratio (mg/mmol) 9 (2–21) 3 (1–19) 11 (6–39) 0.06
AQP2 excretion (ng/24h) 760 (549–2280) 752 (418–2239) 760 (605–3185) 0.62
AQP2/creatinine ratio (μg/mmol) 62 (45–204) 69 (32–206) 58 (45–204) 1.00
ADPKD and IgA Nephropathy patients were matched for age, sex, and eGFR. Data are given as mean±SD for normally distributed data or median (IQR) for
non-normally distributed data. Significance was tested using a chi-square test for categorical data, Student’s t-test for normally distributed data or a Mann-
Whitney U test for non-normally distributed data. Osmolality, urea and creatinine excretion were adjusted for BSA. Abbreviations: IgAN, IgA Nephropathy;
BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; TKV, total kidney volume; hTKV, height adjusted total kidney
volume; AQP2, aquaporin-2.
doi:10.1371/journal.pone.0169263.t001
Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients
PLOS ONE | DOI:10.1371/journal.pone.0169263 January 12, 2017 5 / 14
The AQP2 to creatinine ratio at maximal urine concentration was inversely associated with
maximal urine osmolality. ADPKD patients had a 110 mOsmol/kg lower maximal urine osmo-
lality in comparison with the control group at a similar AQP2 level (St. β = -0.37, p = 0.02,
Table 5). No interactions by study group for the association between AQP2 and the maximal
urine concentrating capacity was found. Furthermore, AQP2 at maximal urine concentration
was positively associated with both copeptin and AVP (Table 6). Having ADPKD or IgAN did
not affect these associations (i.e., no significant interactions with study group).
Associations between copeptin and kidney damage
We investigated whether copeptin was associated with kidney damage. In ADPKD, copeptin
at baseline was univariately associated with the urine albumin to creatine ratio (ACR)
(R = 0.88, p<0.001) and this held also true at maximal urine concentration (R = 0.71,
p = 0.003, Fig 2). The association remained significant after multivariable adjustment for
eGFR and hTKV at baseline (St. β = 0.82, p = 0.001) and was of borderline significance at max-
imal urine concentration (St. β = 0.58, p = 0.06). In the IgAN control group copeptin was not
associated with ACR at baseline, neither crude (p = 0.2) nor after adjustment for eGFR
(p = 0.7). At maximal urine concentration copeptin tended to be associated with ACR in IgAN
controls (R = 0.50, p = 0.06), but this association lost significance after adjustment for eGFR
(p = 0.4). In ADPKD, copeptin was furthermore associated with hTKV (R = 0.58, p = 0.03). Of
Table 2. Measurements in plasma at baseline (5 p.m.) and at maximal urine concentration during a standard prolonged water deprivation test.
Plasma Overall n = 30 ADPKD n = 15 IgAN n = 15 P-value
At baseline
Osmolality (mOsmol/kg) 291±8 289±5 294±10 0.14
Sodium (mmol/L) 140±2.5 141±2.9 140±2.0 0.67
Potassium (mmol/L) 4.3±0.4 4.3±0.4 4.3±0.5 0.97
Urea (mmol/L) 11.2±5.3 10.3±3.7 12.1±6.6 0.35
AVP (pmol/L) 4.4 (1.4–12.0) 2.2 (1.3–14.0) 6.3 (1.4–12.0) 0.49
Copeptin (pmol/L) 11.9 (7.1–28.3) 14.0 (6.1–30.1) 11.9 (7.3–27.7) 0.98
At maximal urine concentration
Osmolality (mOsmol/kg) 294±8 293±6 295±10 0.51
Sodium (mmol/L) 142±1.9 142±2.4 141±1.0 0.10
Potassium (mmol/L) 4.4±0.5 4.3±0.5 4.5±0.6 0.30
Urea (mmol/L) 11.0±5.3 10.3±3.5 11.7±6.6 0.47
AVP (pmol/L) 9.6 (2.4–12.3) 9.2 (1.4–12.0) 10.0 (2.5–13.0) 0.57
Copeptin (pmol/L) 23.7 (10.6–44.6) 26.6 (12.7–43.0) 20.7 (10.0–48.3) 0.84
Change between baseline and maximal urine concentration
Osmolality (%) 0.8±1.2* 1.1±1.2* 0.5±1.1 0.09
Sodium (%) 0.8±1.3* 1.0±1.5* 0.7±1.1* 0.32
Potassium (%) 2.2±6.7 0.1±6.5 4.2±6.5* 0.08
Urea (%) -3.2±11.6 -0.2±7.4 -6.0±14.1 0.14
AVP (%) 86±158* 116±208* 35±61* 0.11
Copeptin (%) 82±89* 94±113* 72±59* 0.51
Data are given as mean±SD for normally distributed data or as median (IQR) for non-normally distributed data. Significance between groups was tested
using Student’s t-test for normally distributed data or a Mann-Whitney U test for non-normally distributed data. Percentage change within groups was tested
using a one-sample t-test,
* p<0.05.
Abbreviations: IgAN, IgA Nephropathy; AVP, vasopressin; AQP2, aquaporin-2.
doi:10.1371/journal.pone.0169263.t002
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note, hTKV was positively associated with plasma osmolality and inversely with urine osmolal-
ity at maximal urine concentration (R = 0.52, p = 0.048, R = -0.54, p = 0.04, respectively).
Baseline U/P Urea as marker for maximal urine concentration capacity
In a previous study, we suggested that the urine-to-plasma urea ratio (U/P Urea), measured
routinely in an out-patient clinic setting, may be a marker for maximal urine concentrating
capacity [20]. We therefore tested in this study also the association between baseline U/P Urea
ratio and maximal urine osmolality. In the two study groups combined (R = 0.73, p<0.001), as
well as in both groups separately, strong associations were found (ADPKD: R = 0.67,
p = 0.006; IgAN control: R = 0.75, p = 0.001, Fig 3). In the total study group, the association
Table 3. Measurements in spot urine at baseline (5 p.m.) and at maximal urine concentration during a standard prolonged water deprivation test.
Spot urine Overall n = 30 ADPKD n = 15 IgAN n = 15 P-value
At baseline
Osmolality (mOsmol/kg) 438±160 378±157 498±144 0.04
Sodium (mmol/L) 66±32 55±29 77±32 0.06
Potassium (mmol/L) 46±21 44±20 49±23 0.46
Urea (mmol/L) 207±81 177±80 237±71 0.04
Creatinine (mmol/L) 7.9±3.8 7.2±4.3 8.7±3.3 0.28
Albumin (mg/L) 98 (38–218) 64 (21–127) 137 (64–476) 0.045
Albumin/creatinine ratio (mg/mmol) 14 (7–29) 9 (3–26) 19 (9–51) 0.10
AQP2 (ng/mL) 986 (283–3396) 584 (171–3297) 1562 (293–3693) 0.54
AQP2/creatinine ratio (μg/mmol) 177 (45–361) 106 (28–532) 189 (50–325) 0.87
At maximal urine concentration
Osmolality (mOsm/kg) 587±151 533±138 642±148 0.046
Sodium (mmol/L) 77±31 75±24 80±38 0.65
Potassium (mmol/L) 81±35 78±28 84±41 0.61
Urea (mmol/L) 261±81 223±74 299±72 0.008
Creatinine (mmol/L) 12.8±4.7 11.5±4.2 14.1±5.1 0.14
Albumin (mg/L) 92 (57–245) 64 (26–130) 160 (86–554) 0.01
Albumin/creatinine ratio (mg/mmol) 10 (4–49) 7 (-13) 11 (9–6) 0.045
AQP2 (ng/mL) 676 (343–1444) 410 (274–2844) 833 (425–1274) 0.33
AQP/creatinine ratio (μg/mmol) 52 (31–130) 33 (21–290) 56 (39–109) 0.60
Change between baseline and maximal urine concentration
Osmolality (%) 52±81* 68±107* 36±41* 0.29
Sodium (%) 37±83* 61±93* 12±66 0.11
Potassium (%) 126±266* 171±370 82±73* 0.37
Urea (%) 40±59* 48±73* 33±42* 0.13
Creatinine (%) 98±139* 118±184* 78±75* 0.44
Albumin (%) 122±455 198±641 45±69* 0.09
Albumin/creatinine ratio (%) -10±60 -7±73 -12±47 0.41
AQP2 (%) 8±98 20±122 -4±68 0.32
AQP/creatinine ratio (%) -43±44* -48±22* -37±59* 0.08
Data are given as mean±SD for normally distributed data or as median (IQR) for non-normally distributed data. Significance was tested using Student’s t-
test for normally distributed data or a Mann-Whitney U test for non-normally distributed data. Percentage change within groups was tested using a one-
sample t-test,
* p<0.05.
Abbreviations: IgAN, IgA Nephropathy; AVP, vasopressin; AQP2, aquaporin-2.
doi:10.1371/journal.pone.0169263.t003
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remained significant after adjustment for age, sex and eGFR (St. β = 0.62, p = 0.003) and
showed a trend towards significance in the separate study groups (ADPKD: St. β = 0.51,
p = 0.1 and IgAN control: St. β = 0.76, p = 0.054). In addition, we tested whether U/P Urea is a
marker for disease severity in ADPKD. Significant associations were found for baseline U/P
urea with hTKV (R = -0.53, p = 0.04) and eGFR (R = 0.60, p = 0.02), and with copeptin at max-
imal urine concentration (R = -0.58, p = 0.03).
Discussion
In the present study we found a more severely impaired urine concentrating capacity in
ADPKD patients with, surprisingly, similar AVP and copeptin responses in comparison with
IgAN control patients at similar low kidney function. Furthermore, more severe ADPKD,
assessed as a higher total kidney volume, was positively associated with plasma osmolality,
copeptin and albuminuria, and with a more severely impaired urine concentrating capacity
during water deprivation.
After water deprivation, concentrations of plasma AVP, plasma copeptin and urine AQP2
were similar in both study groups, whereas the maximal urine concentrating capacity was sig-
nificantly more impaired in ADPKD patients. This shows that the process of urine concentra-
tion is complex and comprises more than solely variation in the permeability of collecting duct
cells. In addition the medullary osmotic gradient is of great importance. This gradient is deter-
mined by a complex mechanism involving intra-renal urea recycling by urea transporters in
the renal medulla. The importance of these urea transporters for urine concentration has been
confirmed in knock-out mouse models [21,22]. Mice with a defect in one or multiple urea
Table 4. Univariate linear regression associations of plasma copeptin and AVP (log transformed) with plasma osmolality and multivariable linear
regression analyses testing the effect of having ADPKD on the associations at baseline and at maximal urine concentration.
Plasma copeptin Crude Model 1 Model 2
R P-value St. β P-value St. β P-value
Baseline
Plasma osmolality 0.60 0.001 0.64 <0.001 0.57 0.004
Study group (ADPKD vs. IgAN) 0.14 0.40 -5.3 0.46
Plasma osmolality x Study group 5.4 0.45
Maximal urine concentration
Plasma osmolality 0.62 <0.001 0.63 <0.001 0.57 0.004
Study group (ADPKD vs. IgAN) 0.10 0.51 -3.8 0.54
Plasma osmolality x Study group 3.9 0.53
Plasma AVP
Baseline
Plasma osmolality 0.32 0.09 0.29 0.14 0.26 0.25
Study group (ADPKD vs. IgAN) -0.10 0.61 -2.77 0.74
Plasma osmolality x Study group 2.66 0.75
Maximal urine concentration
Plasma osmolality 0.34 0.06 0.34 0.08 0.29 0.20
Study group (ADPKD vs. IgAN) -0.03 0.85 -3.35 0.66
Plasma osmolality x Study group 3.31 0.66
Standardized betas (St. β) and p-values were calculated using multivariable linear regression. Dependent variables are plasma copeptin and AVP (log
transformed), independent variables are plasma osmolality, the categorical variable study group (1 = ADPKD, 0 = IgAN) and the interaction term between
plasma osmolality and study group. Abbreviations: IgAN, IgA nepghropathy; AVP, vasopressin.
doi:10.1371/journal.pone.0169263.t004
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transporters were still able to concentrate urine, but to a lesser extent than wild-type mice, due
to a reduced urea clearance, whereas sodium and other electrolytes were cleared in a similar
way. In APDKD signs of such a urea selective concentrating defect can be observed as well. In
a previous study we found that ADPKD patients with preserved kidney function had at maxi-
mal urine concentration markedly lower urine urea levels compared to healthy controls (280
±56 mmol/L vs. 405±110 mmol/L, p = 0.001) [4]. We hypothesized that in ADPKD patients
cyst formation disrupts the medullar osmotic gradient and urea recycling. The present study
suggests that this difference in solute clearance seems ADPKD-specific and is not part of kid-
ney damage in general, as urine urea levels at maximal urine concentration were lower in
ADPKD patients than in the IgAN control group despite similar level of impaired kidney func-
tion. In addition, when comparing urine urea concentrations at the moment of maximal urine
concentration in ADPKD with preserved kidney function [23] with findings from the present
study, it shows that urine urea concentration decreases when disease progresses (preserved
kidney function: 280±56 mmol/L, impaired kidney function: 223±74 mmol/L, p = 0.03). The
Fig 1. Associations of copeptin and vasopressin concentration with plasma osmolality and urine osmolality in ADPKD patients
(solid line) and IgA Nephropathy patients (IgAN, dashed line) at maximal urine concentration.
doi:10.1371/journal.pone.0169263.g001
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fact that the U/P urea ratio correlates well with maximal urine concentrating capacity shows
the importance of urea in the urine concentration process as well.
After water deprivation, the increase in copeptin and AVP was similar in both study groups,
even though the maximal urine concentrating capacity was more impaired and the increase in
plasma osmolality seemed more profound in ADPKD patients in comparison to the control
group. In both groups plasma osmolality was comparable at the end of the water deprivation
test, which could be the explanation for similar copeptin and AVP levels at the moment of
maximal urine concentration. On the other hand, Ho et al. have described the possibility of a
Table 5. Linear regression analyses of urine osmolality with plasma copeptin, AVP and urine AQP2/creatinine ratio (all log transformed) at maxi-
mal urine concentration, including analyses testing whether study group (i.e. having ADPKD) interacts with these associations.
Urine osmolality Crude Model 1 Model 2
R P-value St. β P-value St. β P-value
Plasma copeptin
Plasma copeptin -0.66 <0.001 -0.66 <0.001 -0.61 0.001
Study group (ADPKD vs. IgAN) -0.35 0.01 -0.13 0.81
Plasma copeptin x Study group -0.24 0.67
Plasma AVP
Plasma AVP -0.41 0.03 -0.44 0.01 -0.47 0.06
Study group (ADPKD vs. IgAN) -0.40 0.02 -0.45 0.17
Plasma AVP x Study group 0.06 0.87
Urine AQP2/creatinine
Urine AQP2/creatinine -0.51 0.004 -0.52 0.002 -0.58 0.06
Study group (ADPKD vs. IgAN) -0.37 0.02 -0.53 0.44
Urine AQP2/creatinine x Study group 0.17 0.82
Standardized beta coefficients (St. β) and p-values were calculated using linear regression. Dependent variable is urine osmolality, independent variables
are plasma copeptin (log transformed), plasma AVP (log transformed), urine AQP2/creatinine (log transformed), the categorical variable study group and
the interaction term between plasma copeptin, AVP or urine AQP2/creatinine and study group. Abbreviations: IgAN, IgA Nephropathy; AVP, vasopressin;
AQP2, aquaporin-2.
doi:10.1371/journal.pone.0169263.t005
Table 6. Univariate linear regression associations of the urine AQP2 to creatinine ratio with plasma copeptin or AVP (both log transformed) at
maximal urine concentration and multivariable linear regression analyses testing the effect of having ADPKD on these associations.
Urine AQP2/creatinine Crude Model 1 Model 2
R P-value St. β P-value St. β P-value
Plasma copeptin
Plasma copeptin 0.49 0.006 0.49 0.006 0.38 0.09
Study group (ADPKD vs. IgAN) -0.02 0.92 -0.59 0.40
Plasma copeptin x Study group 0.61 0.40
Plasma AVP
Plasma AVP 0.45 0.01 0.46 0.01 0.33 0.20
Study group (ADPKD vs. IgAN) 0.03 0.87 -0.17 0.63
Plasma AVP x Study group 0.25 0.52
Standardized beta coefficients (St. β) and p-values were calculated using multivariable linear regression. Dependent variable is urine AQP2/creatinine (log
transformed), independent variables are plasma copeptin (log transformed), plasma AVP (log transformed), the categorical variable study group
(1 = ADPKD, 0 = IgAN) and the interaction term between plasma copeptin or AVP and study group. Abbreviations: AQP2, aquaporin-2; IgAN, IgA
Nephropathy; AVP, vasopressin.
doi:10.1371/journal.pone.0169263.t006
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central component causing the impaired urine concentrating capacity in ADPKD. These
authors hypothesized that expression of PKD1 and PKD2 transcripts in hypothalamic nuclei
that synthesize AVP could be involved [24]. They found in ADPKD patients a lower maximal
urine osmolality in comparison with healthy controls, but no AVP response during water
Fig 2. Associations of plasma copeptin concentration with urine albumin to creatinine ratio in ADPKD (solid line)
and IgA Nephropathy (IgAN, dashed line) patients at maximal urine concentration.
doi:10.1371/journal.pone.0169263.g002
Fig 3. Associations of maximal urine osmolality with baseline urine-to-plasma (U/P) urea ratio in ADPKD
patients (solid line) and IgA Nephropathy patients (IgAN, dashed line).
doi:10.1371/journal.pone.0169263.g003
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deprivation. They also did not find an association between AVP and plasma osmolality, and
suggested that AVP secretion was blunted in ADPKD patients. In our study, a significant
response in both copeptin and AVP was seen. Nevertheless, we found no association between
plasma osmolality and AVP as well, suggesting that a central component may play a role. How-
ever, an association between plasma osmolality and copeptin was present. The latter suggests
that copeptin and therefore also AVP secretion responded appropriately to plasma osmolality,
which makes a central component less likely. The contradictory results between AVP and
copeptin that are seen in our study may be explained by differences in assay sensitivity, as
copeptin is more stable than AVP ex-vivo and therefore probably more reliable to measure
[4,12–14]. Based on our results a central component in the impaired maximal urine concentra-
tion capacity in ADPKD seems unlikely but cannot be excluded.
In this study ADPKD patients with later stages of disease showed markedly higher AVP
and copeptin levels at the end of a water deprivation test compared to levels that were
achieved in our previous study that was performed in ADPKD patients with earlier stages of
disease (9.2 (1.4–12.0) pmol/L vs. 1.6 (1.13–2.41) pmol/L, p = 0.007) [4]. It is assumed that
AVP has a detrimental role in ADPKD, because it leads to an increase in intracellular cAMP
in distal tubular cells, which in turn leads to cell proliferation and increased fluid section, the
processes that drive cyst formation and growth [25]. When cysts are formed and expand
because of a genetic defect, urine concentrating capacity decreases, leading to an increase in
AVP and consequently to even more cyst formation and expansion. Thus a vicious circle is
created that predisposes for kidney growth and loss of kidney function. To reduce cyst
growth, an increase in AVP levels should be avoided. Our study results indicate that thirsting
enhances AVP release, also in ADPKD, and suggest that dehydration should be avoided in
this patient group.
The major strength of our study is the inclusion of a control group of eGFR-, age- and sex-
matched IgAN patients. This allowed us to conclude whether our observations in ADPKD
patients are disease specific or due to impaired eGFR, without misinterpreting data due to dif-
ferences in age and sex distribution. These latter factors have been shown to be associated with
maximal urine concentrating capacity [11,26,27]. In addition, we measured both AVP and
copeptin levels. Therefore we were able to confirm outcomes with respect to AVP that showed
a trend toward significance, with copeptin values that are more easy and reliable to measure.
Using copeptin levels we indeed were able to detect more subtle associations and differences
between the two study groups. Some limitations need to be addressed. First, the relatively
small sample size. No data on urine concentration capacity of IgAN patients was available
from literature to perform a power calculation a priori. Therefore the size of our study popula-
tion was based on experience obtained in a previous water deprivation test [4]. Although dif-
ferences between the present study groups were less profound compared to the differences
between study groups in our previous study, our main findings are clear and well powered
(i.e., statistically significant). Second, 24h urine volume was significantly higher in ADPKD
patients in comparison to IgAN controls. This was probably due to the fact that ADPKD
patients in our department are used to hydrate properly. Because baseline was not standard-
ized, this led to lower urine and plasma osmolality in ADPKD patients at baseline. However,
our conclusions are based on the standardized results found after water deprivation. Third,
our study design may not be optimal to detect a central component causing partial diabetes
insipidus. We used a standard prolonged water deprivation test, which can distinguish
between a complete central or nephrogenic origin of diabetes insipidus, but is less accurate in
detecting partial and especially mixed syndromes [16]. Lastly, the control group consisted of
only IgAN patients. We preferred this option over including patients with a case mix of dis-
eases with uncertain results.
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In conclusion, ADPKD patients have a more severely impaired maximal urine concentrat-
ing capacity with a lower maximal achieved urine urea concentration in comparison to IgAN
control patients with a similar level of decreased kidney function. AVP secretion as response
to water deprivation was similar in both groups. When disease progresses, AVP secretion
upon thirsting increases in ADPKD patients. This increase in AVP can be harmful as AVP is
known to enhance cell proliferation and cyst formation. Water deprivation may therefore be
deleterious and should be avoided by ADPKD patients.
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